Navigation Links
Savient Pharmaceuticals To Hold Fourth Quarter And Year-End 2009 Results Conference Call On Friday, February 26, 2010
Date:2/8/2010

EAST BRUNSWICK, N.J., Feb. 8 /PRNewswire-FirstCall/ -- Savient Pharmaceuticals, Inc. (Nasdaq: SVNT) announced today that the company will release financial results for the fourth quarter and year-end 2009 following the close of the market on Thursday, February 25, 2010.

Paul Hamelin, President and David Gionco, Group Vice President and Chief Financial Officer, will host an investment community conference call beginning at 10:00 a.m. Eastern Time on February 26, 2010 to discuss these results and to answer questions.

To participate by telephone, please dial 888-357-3694 (Domestic) or 973-890-8276 (International). The conference identification number is 53622474. The live and archived webcast can be accessed on the investor relations section of the Savient website at www.savient.com. Please log on to Savient's website 15 minutes prior to the start of the call to ensure adequate time for any downloads that may be necessary.

A telephone replay will be available from 1:00 p.m. Eastern Time on February 26, 2010 through 11:59 p.m. Eastern Time on March 12, 2010 by dialing 800-642-1687 (Domestic) or 706-645-9291 (International) and entering conference ID number 53622474.

ABOUT SAVIENT PHARMACEUTICALS, INC.

Savient Pharmaceuticals, Inc. is a specialty biopharmaceutical company focused on developing KRYSTEXXA™ (pegloticase) for the treatment of chronic gout in patients refractory to conventional therapy. Savient has exclusively licensed worldwide rights to the technology related to KRYSTEXXA, formerly referred to as Puricase®, from Duke University and Mountain View Pharmaceuticals, Inc. Savient also manufactures and supplies Oxandrin® (oxandrolone tablets, USP) CIII in the U.S. Puricase is a registered trademark of Mountain View Pharmaceuticals, Inc.

SOURCE Savient Pharmaceuticals, Inc.

RELATED LINKS
http://www.savient.com

'/>"/>

SOURCE Savient Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Savient Announces FDAs Advisory Panel to Review Pegloticase for Treatment-Failure Gout Patients
2. Savient Provides Update on Pegloticase BLA
3. Savient Pharmaceuticals Announces Proposed Public Offering of Common Stock
4. Savient Pharmaceuticals Prices Underwritten Offering of Common Stock
5. Savient Pharmaceuticals Announces Closing of Public Offering and Exercise of Over-Allotment Option
6. Savient Pharmaceuticals Reports Third Quarter 2009 Financial Results
7. Savient Provides Update on KRYSTEXXA(TM) BLA Resubmission Activities
8. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
9. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
10. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
11. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/23/2017)... SPRING, Md. , March 23, 2017  The ... to Bavencio (avelumab) for the treatment of adults and ... cell carcinoma (MCC), including those who have not received ... metastatic MCC, a rare, aggressive form of skin cancer. ... most common cancers, patients with a rare form called ...
(Date:3/23/2017)... 2017   Icertis , the leading provider ... cloud, today announced an upgrade to the Icertis ... improve clinical trials contract management. Built on the ... solution speeds up clinical trial contracting while improving ... "The pharmaceutical industry is under ...
(Date:3/23/2017)... 23, 2017 A research report by ... expected to reach USD 7.2 billion by the end of ... is a procedure in which a sample is preserved prior ... analytical procedures since the methods are often allowing repeated testing. ... the most shared procedures in the lab. In many life ...
Breaking Medicine Technology:
(Date:3/24/2017)... ... March 24, 2017 , ... ... Walk with God #TruthwithGrace”: a devotional journal chronicling the writer’s path toward true ... How to Walk with God #TruthwithGrace” is the creation of published author Lea ...
(Date:3/24/2017)... ... ... “The Adventures of Joey, The Dog Who Barks at Puddles”: a boisterous story about ... as God intended. “The Adventures of Joey, The Dog Who Barks at Puddles” is ... for writing, especially about truth and human behavior. , Published by Christian Faith Publishing, ...
(Date:3/23/2017)... ... 23, 2017 , ... Demonstrating their commitment to improving health ... departments have been awarded national accreditation through the Public Health Accreditation Board ... network of communities across the nation whose health departments meet rigorous national standards ...
(Date:3/23/2017)... and Grimsby, Ontario (PRWEB) , ... March 23, 2017 , ... The MBI “Hall of ... industry or whose acts have had a significant impact on the careers of all others ... Marketing with NRB Inc. was inducted into the MBI’s Hall of Fame. The induction ...
(Date:3/23/2017)... ... March 23, 2017 , ... ... SmartBen NOW, an innovative mobile app and centralized benefits dashboard solving one of ... information securely from multiple locations. For the first time, employees can access up-to-date ...
Breaking Medicine News(10 mins):